Background
At a KOSDAQ-listed company in the medical and healthcare sector, minority shareholders brought a derivative suit on the company's behalf (Commercial Act art. 403) against current and former management (including a former representative director) suspected of causing loss to the company. Changchun lent its support by intervening as an auxiliary party on the shareholders' side.
The Issue — Whose Liability, and How Far?
An earlier derivative suit was already under way, and there were multiple defendants. The key questions were ① whether Changchun could properly intervene and take part in the proceedings, and ② which of the jointly liable officers' claims to consolidate and maintain so as to secure realistic prospects of enforcement.
How Changchun Helped
Changchun (attorneys Jaesun Yoon, Donghwan Shin and Jonghwa Kim) designed the procedure strategically: ① securing standing to take part through an application for auxiliary intervention (permission granted); ② once intervention was permitted, partially tidying up duplicative claims against defendants already being pursued (withdrawal of those claims); while ③ maintaining and consolidating the claims, with future enforceability in mind, against an officer who was jointly liable but not a party to the earlier suit.
The derivative suit is a mechanism by which shareholders pursue, on the company's behalf, the management liability a company finds hard to pursue itself. Changchun takes an active part in that pursuit on the side of minority shareholders. (Outcomes may differ depending on the facts of each matter.)